UNSPSC 51434818: Sornidipine

This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z82YP691V7. European Medicines Agency schedules Sornidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10606MIG. Sornidipine generally arises in the molecular formula C22H24N2O9.

UNSPSC 51434818 Sornidipine, a Commodity code, classifies individual pharmaceutical products procured by state and local governments for emergency medical services, pharmacy benefit programs, and multistate cooperative purchasing networks. State and local buyers under this code purchase specific branded or generic medications for fire rescue services, state health agencies, and health plan administrators seeking to manage prescription costs through direct-to-manufacturer relationships or consolidated purchasing arrangements. The issuing bodies span municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Recent activity shows municipal and state-level buyers acquiring medications through multiple procurement vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem—for Tampa Fire Rescue with an estimated contract value of $40,000 and a SLBE sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct contracting relationships outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, effective July 1, 2026. Activity concentrates in Texas, Minnesota, Florida, and Oregon, with procurement models ranging from emergency-services medication resupply to statewide pharmacy benefit initiatives and interstate cooperative purchasing frameworks.